Document is current
Any future updates will be listed below
-
Authors
Creyns, Brecht https://orcid.org/0000-0002-1634-8875
Cremer, Jonathan
Hoshino, Tomoaki
Geboes, Karel
de Hertogh, Gert
Ferrante, Marc
Vermeire, Séverine https://orcid.org/0000-0001-9942-3019
Ceuppens, Jan L.
Van Assche, Gert
Breynaert, Christine
- License Information
-
More Information
Article History
Received: 8 January 2019
Accepted: 28 June 2019
First Online: 11 July 2019
Competing Interests
: M.F. received financial support for research from Pfizer, Takeda and Janssen; lecture fees from Ferring, Boehringer- Ingelheim, Chiesi, Merck Sharpe & Dohme, Tillotts, Janssen Biologics, Abbvie, Takeda, Mitsubishi Tanabe, Zeria; consultancy fees from Abbvie, Boehringer-Ingelheim, Ferring, Merck Sharpe & Dohme, and Janssen Biologics. G.V.A. reports financial support for research from Abbott and Ferring Pharmaceuticals; lecture fees from Janssen, MSD and Abbott; consultancy fees from PDL BioPharma, UCB Pharma, Sanofi-Aventis, Abbott, Abbvie, Ferring, Novartis, Biogen Idec, Janssen Biologics, NovoNordisk, Zealand Pharma A/S, Millenium/Takeda, Shire, Novartis and Bristol Mayer Squibb. SV reports financial support for research: MSD, AbbVie, Takeda, Pfizer, J&J; Lecture fees: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Genentech/Roche; Consultancy: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Genentech/Roche, Celgene, Mundipharma, Celltrion, SecondGenome, Prometheus, Shire, Prodigest, Gilead, Galapagos.
